Turmeric for Patients With Basal Joint Arthritis | NCT03017118

Studies
Turmeric for Patients With Basal Joint Arthritis

NCT03017118

Sponsor

Massachusetts General Hospital

Status

Recruiting

Last Update Posted

Nov 24, 2025Actual

Enrollment

60Estimated

Phase

Not Applicable

Conditions

Thumb Osteoarthritis

Interventions

Turmeric
Placebo

Countries

United States

Protocol Section

Identification Module Status Module Sponsor/Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms/Interventions Module Outcomes Module Eligibility Module Contacts/Locations Module References Module IPD Sharing Statement Module

Results Section

Participant Flow Module Baseline Characteristics Module Outcome Measures Module Adverse Events Module More Info Module

Annotation Section

Annotation Module

Document Section

Large Document Module

Derived Section

Miscellaneous Info Module Condition Browse Module Intervention Browse Module

Protocol Section

Identification Module

NCT ID

Results Section

No data available

No data is available for this block.

Annotation Section

No data available

No data is available for this block.

Document Section

No data available

No data is available for this block.

Derived Section

Miscellaneous Info Module

Version Holder

Status Module

Record Verification Date

Nov 2025

Overall Recruitment Status or Expanded Access Status

Recruiting

Last Known Status

Not provided

Delayed Posting

Not provided

Why Stopped

Not provided

Expanded Access Info

Start Date

Aug 9, 2017Actual

Primary Completion Date

Dec 2027Estimated

Completion Date

Jan 2028Estimated

First Submitted Date

Dec 7, 2016

First Submission Date that Met QC Criteria

Jan 9, 2017

First Posted Date

Jan 11, 2017Estimated

Results Waived

Not provided

Results First Submitted Date

Not provided

Results First Submitted that Met QC Criteria

Not provided

Results First Posted Date

Not provided

Certification/Extension (aka Delayed Results) First Submitted Date

Not provided

Certification/Extension First Submitted that Passed QC Review

Not provided

Certification/Extension First Posted Date

Not provided

Last Update Submitted Date

Nov 19, 2025

Last Update Posted Date

Nov 24, 2025Actual

Oversight Module

Has Data Monitoring Committee (DMC)

Is FDA Regulated Drug

Is FDA Regulated Device

Is Unapproved Device

Not provided

Pediatric Postmarket Surveillance of a Device Product

Not provided

Product Exported from US

Not provided

FDAAA801 Violation

Not provided

Description Module

Brief Summary

The aim of this study is to assess whether the use of a commercially available nutraceutical, turmeric, is an effective option to manage pain and stiffness in patients with basal joint arthritis. To conduct a pilot Randomized Controlled Trial evaluating the impact of turmeric on basal joint arthritis.

Detailed Description

Not provided

Design Module

Study Type

Interventional

Number of References to an Expanded Access Study

Not provided

Expanded Access Types

Not provided

Patient Registry

Not provided

Target Follow-Up Duration

Not provided

Phases

Not Applicable

Interventional Study Design

Allocation

Biospecimen

No data available

No data is available for this block.

Enrollment

60Estimated

Arms/Interventions Module

Arm Groups

Label	Type	Description	Intervention Names
Turmeric	Experimental	Subjects in this group will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.	Dietary Supplement: Turmeric
Control	Placebo Comparator	Subjects in this group will receive a placebo pill 3 times per day for 6 weeks.	Other: Placebo

Interventions

Name	Type	Description	Arm Group Labels	Other Names
Turmeric	Dietary Supplement	Subjects will receive turmeric (100 mg pastille) 3 times per day for 6 weeks.	Turmeric

Outcomes Module

Primary Outcomes

Measure	Description	Time Frame
Change in baseline pain intensity	0-10 ordinal rating of pain intensity	Enrollment, 6 weeks, and 3 months
Change in baseline disability	Disability measured by the QuickDASH	Enrollment, 6 weeks, and 3 months

Secondary Outcomes

Not provided

Other Outcomes

Not provided

Eligibility Module

Eligibility Criteria

Inclusion Criteria:

40 years of age or older
English fluency and literacy
Seeking care for basal joint pain
Tender over basal joint
Positive distraction rotation test (rotation of the thumb metacarpal base while applying axial traction)
Radiographic evidence of Eaton stage 1 and 2 only

Exclusion Criteria:

Secondary gains (litigations or worker compensation) procedures that may interfere with patients' motivation for treatment
Inability or unwillingness to participate in a trial study
Rheumatoid Arthritis or other inflammatory disorder diagnoses
Post-traumatic osteoarthritis
Patients on Coumadin/Steroids/NSAIDs/Tylenol
Diabetes Mellitus
Pregnant or lactating women
Basal joint arthritis of Eaton stage 3
Patients seeking other treatment for their basal joint arthritis (splint, corticosteroid injection, surgery)

Accepts Healthy Volunteers

Sex

All

Sex/Gender Based

Not provided

Sex/Gender Description

Not provided

Minimum Age

40 Years

Maximum Age

Not provided

Standard Ages

AdultOlder Adult

Study Population

Not provided

Sampling Method

Not provided

Contacts/Locations Module

Central Contacts

Name	Role	Phone	Extension	Email
Neal Chen, M.D.	Contact	617-726-4700		nchen1@mgh.harvard.edu
Karan Amin, BA	Contact			kamin2@mgh.harvard.edu

Overall Officials

Name	Affiliation	Role
Neal Chen, MD	Massachusetts General Hospital	Principal Investigator

Locations

Facility	Status	City	State	ZIP	Country	Contacts
Massachusetts General Hospital	Recruiting	Boston	Massachusetts	02114	United States

Intervention Browse Module

MeSH Terms

ID	Term
D003474	Curcumin

Ancestor Terms

ID	Term
D036381	Diarylheptanoids
D006536	Heptanes
D000473	Alkanes
D006839	Hydrocarbons, Acyclic

Browse Leaves

Not provided

Browse Branches

Not provided